Astrazeneca Plc $AZN Shares Sold by Traveka Wealth LLC

Traveka Wealth LLC trimmed its holdings in Astrazeneca Plc (NYSE:AZN) by 50.5% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 3,417 shares of the company’s stock after selling 3,481 shares during the period. Traveka Wealth LLC’s holdings in Astrazeneca were worth $674,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. IHT Wealth Management LLC lifted its stake in shares of Astrazeneca by 0.3% in the 4th quarter. IHT Wealth Management LLC now owns 17,527 shares of the company’s stock valued at $3,076,000 after purchasing an additional 54 shares during the last quarter. Visionary Wealth Advisors grew its holdings in shares of Astrazeneca by 1.5% during the 4th quarter. Visionary Wealth Advisors now owns 4,197 shares of the company’s stock worth $737,000 after purchasing an additional 60 shares during the period. Vista Investment Management increased its position in shares of Astrazeneca by 0.3% during the 4th quarter. Vista Investment Management now owns 21,215 shares of the company’s stock worth $3,723,000 after purchasing an additional 60 shares during the last quarter. Kestra Investment Management LLC increased its position in shares of Astrazeneca by 1.9% during the 4th quarter. Kestra Investment Management LLC now owns 3,391 shares of the company’s stock worth $595,000 after purchasing an additional 63 shares during the last quarter. Finally, Luken Investment Analytics LLC raised its holdings in Astrazeneca by 4.3% in the 4th quarter. Luken Investment Analytics LLC now owns 1,564 shares of the company’s stock valued at $274,000 after buying an additional 64 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Ratings Changes

AZN has been the topic of a number of recent analyst reports. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Friday. Morgan Stanley reiterated an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Barclays reissued a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. DZ Bank upgraded shares of Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 9th. Twelve analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Stock Up 1.6%

Shares of NYSE:AZN opened at $188.58 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. The firm has a market capitalization of $292.47 billion, a PE ratio of 28.32, a price-to-earnings-growth ratio of 1.64 and a beta of 0.25. The firm’s 50-day moving average is $184.66 and its two-hundred day moving average is $187.05. Astrazeneca Plc has a 1 year low of $137.23 and a 1 year high of $212.71.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The business had revenue of $15.29 billion for the quarter, compared to analysts’ expectations of $14.93 billion. Analysts predict that Astrazeneca Plc will post 9.39 EPS for the current year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.